Mezzion Pharma Co.,Ltd. (KOSDAQ:140410)
South Korea
· Delayed Price · Currency is KRW 95,900
+3,100 (3.34%)
Apr 29, 2026, 2:50 PM KST
Mezzion Pharma Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Operating Revenue | 7,910 | 8,612 | 31,721 | 30,726 | 26,654 | Upgrade
|
| Other Revenue | - | - | -0 | - | - | Upgrade
|
| Revenue | 7,910 | 8,612 | 31,721 | 30,726 | 26,654 | Upgrade
|
| Revenue Growth (YoY) | -8.15% | -72.85% | 3.24% | 15.28% | -6.92% | Upgrade
|
| Cost of Revenue | 6,529 | 6,701 | 27,836 | 31,040 | 22,956 | Upgrade
|
| Gross Profit | 1,381 | 1,910 | 3,884 | -313.44 | 3,698 | Upgrade
|
| Selling, General & Admin | 15,973 | 14,958 | 16,142 | 19,510 | 17,283 | Upgrade
|
| Research & Development | 1,260 | 294.04 | 938.97 | 2,217 | 1,956 | Upgrade
|
| Operating Expenses | 18,221 | 16,210 | 18,373 | 23,018 | 20,496 | Upgrade
|
| Operating Income | -16,840 | -14,300 | -14,489 | -23,331 | -16,798 | Upgrade
|
| Interest Expense | -1,572 | -300.79 | -315.46 | -423.44 | -323.41 | Upgrade
|
| Interest & Investment Income | 621.96 | 1,431 | 1,477 | 763.35 | 306.23 | Upgrade
|
| Currency Exchange Gain (Loss) | -71.67 | 286.56 | 996.94 | 3,177 | 3,700 | Upgrade
|
| Other Non Operating Income (Expenses) | -21,020 | -1,180 | -157.21 | -1,410 | 90.67 | Upgrade
|
| EBT Excluding Unusual Items | -38,882 | -14,062 | -12,488 | -21,225 | -13,025 | Upgrade
|
| Gain (Loss) on Sale of Assets | 44.05 | -471.69 | 7.35 | 8.99 | -1.08 | Upgrade
|
| Asset Writedown | - | - | - | -14,694 | - | Upgrade
|
| Pretax Income | -38,838 | -14,534 | -12,480 | -35,910 | -13,026 | Upgrade
|
| Income Tax Expense | -3,909 | 4,943 | 248.07 | 388.23 | 577.06 | Upgrade
|
| Earnings From Continuing Operations | -34,929 | -19,477 | -12,728 | -36,298 | -13,603 | Upgrade
|
| Net Income | -34,929 | -19,477 | -12,728 | -36,298 | -13,603 | Upgrade
|
| Net Income to Common | -34,929 | -19,477 | -12,728 | -36,298 | -13,603 | Upgrade
|
| Shares Outstanding (Basic) | 30 | 30 | 28 | 27 | 27 | Upgrade
|
| Shares Outstanding (Diluted) | 30 | 30 | 28 | 27 | 27 | Upgrade
|
| Shares Change (YoY) | 0.95% | 5.62% | 5.63% | 0.17% | 2.63% | Upgrade
|
| EPS (Basic) | -1160.00 | -653.00 | -450.74 | -1357.81 | -509.70 | Upgrade
|
| EPS (Diluted) | -1160.00 | -653.00 | -451.00 | -1358.00 | -510.00 | Upgrade
|
| Free Cash Flow | -16,725 | -19,080 | -11,553 | -12,842 | -15,429 | Upgrade
|
| Free Cash Flow Per Share | -555.46 | -639.69 | -409.10 | -480.39 | -578.14 | Upgrade
|
| Gross Margin | 17.46% | 22.18% | 12.25% | -1.02% | 13.88% | Upgrade
|
| Operating Margin | -212.91% | -166.05% | -45.67% | -75.93% | -63.02% | Upgrade
|
| Profit Margin | -441.61% | -226.17% | -40.13% | -118.13% | -51.03% | Upgrade
|
| Free Cash Flow Margin | -211.46% | -221.56% | -36.42% | -41.80% | -57.89% | Upgrade
|
| EBITDA | -15,852 | -13,342 | -12,942 | -21,673 | -15,212 | Upgrade
|
| EBITDA Margin | -200.42% | -154.93% | -40.80% | -70.54% | -57.07% | Upgrade
|
| D&A For EBITDA | 988.12 | 957.8 | 1,546 | 1,658 | 1,586 | Upgrade
|
| EBIT | -16,840 | -14,300 | -14,489 | -23,331 | -16,798 | Upgrade
|
| EBIT Margin | -212.91% | -166.05% | -45.67% | -75.93% | -63.02% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.